Torsdag 26 December | 11:24:17 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-03-06 N/A Kvartalsrapport 2025-Q2
2024-11-11 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2024-11-08 - Årsstämma
2024-09-20 - Bokslutskommuniké 2024
2024-03-07 - Kvartalsrapport 2024-Q2
2023-11-17 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2023-11-16 - Årsstämma
2023-09-28 - Bokslutskommuniké 2023
2023-04-24 - Extra Bolagsstämma 2023
2023-03-23 - Kvartalsrapport 2023-Q2
2022-11-17 - Årsstämma
2022-10-25 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 - Bokslutskommuniké 2022
2022-06-29 - Extra Bolagsstämma 2022
2022-02-24 - Kvartalsrapport 2022-Q2
2021-10-29 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 - Årsstämma
2021-09-15 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.
2024-06-27 15:15:00

Nightingale Health Plc
Press release
27 June 2024 at 4:15 p.m. (EEST)

Nightingale Health Plc ("Nightingale Health"), a pioneer in disease risk detection and preventative health, and ZOE Limited ("ZOE"), a health science company running the largest in-depth nutrition study in the world, are expanding their longstanding research collaboration. This new phase introduces Nightingale Health's innovative blood collection device for self-collected blood samples and its analysis technology, enhancing the depth and scope of ZOE's research in nutrition and overall health. ZOE uses the results of its research to further develop its market-leading personalized nutrition service, which includes at-home health tests and personalized advice based on the test results.

For several years, blood biomarkers analyzed by Nightingale Health's proprietary high-throughput analysis technology have been used by ZOE's research team, which includes renowned scientists Tim Spector and Sarah Berry. Their work has significantly advanced the understanding of how nutrition impacts human health. By incorporating Nightingale Health's data, ZOE's personalized nutrition research and product offering have been enriched, particularly in understanding the body's core metabolic functions and their relation to common chronic diseases.

A key feature of this expanded collaboration is Nightingale Health's blood collection device, which allows study participants to self-collect their blood samples from a finger prick. As the only fully integrated solution in the self-testing market, the innovation is made possible by the Velvet™ blood collection device owned by Nightingale Health and the seamless integration with the company's proprietary blood analysis technology that can analyze a wide variety of biomarkers from the self-collected sample in one analysis. This breakthrough provides more comprehensive health data than any other solution and enhances the quality of data derived from self-collected blood samples while simultaneously improving the participant experience. It also allows for more flexible study designs and reduces overall research costs.

"This integration of self-collected blood samples analyzed by Nightingale Health's proprietary technology in ZOE's nutrition research represents a step forward in personalized nutrition research. It underscores both companies' commitment to advancing the understanding of nutrition's role in health and disease prevention," says Teemu Suna, Nightingale Health's CEO and Founder.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Nightingale Health

Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world's most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale's Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com 

About ZOE
ZOE is a nutrition science company that runs the world's largest nutrition-science study. Using data at a scale not previously imagined, we're improving the health of millions and unraveling the complex relationship between food, lifestyle and health. The ZOE programme starts with an at-home test and gives our members tailored insights into how to eat for their bodies and long-term health. 

Our science is rooted in the understanding that everyone responds to food differently and that our gut bacteria play an important role in our health. Research from ZOE has been published in leading scientific journals, such as Nature Medicine (https://www.nature.com/articles/s41591-020-0934-0), Nature Metabolism (https://www.nature.com/articles/s42255-021-00383-x), The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31281-2/fulltext), Gut (https://gut.bmj.com/content/70/9/1665) and more.

Located in London and Boston, ZOE was founded by Professor Tim Spector of King's College London, data science leader Jonathan Wolf, and entrepreneur George Hadjigeorgiou.

For more information on our mission and science, visit www.zoe.com (http://www.joinzoe.com).